Cancer drug developer Parthenon Therapeutics secured the funding in a series A round co-led by Pfizer Ventures and Taiho Ventures.
Pharmaceutical firms Pfizer and Taiho co-led a $65m series A round for US-based oncology therapy developer Parthenon Therapeutics yesterday through corporate venturing units Pfizer Ventures and Taiho Ventures.
The round was co-led with venture capital firm Northpond Ventures and included Alexandria Venture Investments, the VC arm of life sciences real estate investment trust Alexandria Real Estate Equities.
Section 32, Breakout Ventures, Creacion Ventures, KdT Ventures and Park West Asset Management filled out the round’s participants together with funds managed by…
